InMed Pharmaceuticals Inc.INM
What InMed Pharmaceuticals Inc. does.
We are a pharmaceutical drug development company with a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease. CB1 and CB2 receptors are each part of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions. CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are involved in modulating neuroinflammation and immune responses. Our research efforts target the treatment of diseases with high unmet medical needs. On March 4, 2026, the InMed Board ratified, confirmed and approved the decision of the board members of BayMedica to wind down and exit BayMedica’s commercial operations business segment, which constitutes the only revenue-generating commercial operations of InMed. As of June 30, 2026, BayMedica had wound down all of its operating activities, and had two remaining employees who departed on July 31, 2026, as well as a commercial lease which will terminate at the end of August. Following the wind down of commercial operations, InMed’s remaining activities have consisted of preclinical development of its Product Candidates, including INM-901 for Alzheimer’s disease, INM-089 for dry Age-related Macular Degeneration or dry AMD, and INM-755 (cannabinol) cream. InMed does not currently intend to devote significant resources to advancing these Product Candidates, and any further development of them would require InMed to obtain additional financing, of which there can be no assurance.
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | $1.9M | $1.1M | $4.1M | $4.6M | $4.9M | — |
| Net income | -$10.2M | -$18.6M | -$7.9M | -$7.7M | -$8.2M | -$12.6M |
| Free cash flow | -$9.8M | -$15.6M | -$7.4M | -$7.0M | — | — |
More on INM.
- InMed Pharmaceuticals Inc. summary
- InMed Pharmaceuticals Inc. financial statements
- InMed Pharmaceuticals Inc. key metrics
- InMed Pharmaceuticals Inc. health scores and style box
- InMed Pharmaceuticals Inc. earnings
- InMed Pharmaceuticals Inc. dividends
- InMed Pharmaceuticals Inc. valuation
- InMed Pharmaceuticals Inc. ownership and insiders
- InMed Pharmaceuticals Inc. peers
Figures from InMed Pharmaceuticals Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.